Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

61.30USD
19 Dec 2014
Price Change (% chg)

$0.51 (+0.84%)
Prev Close
$60.79
Open
$60.84
Day's High
$61.64
Day's Low
$60.60
Volume
10,975,053
Avg. Vol
6,890,209
52-wk High
$61.64
52-wk Low
$46.30

BMY

Chart for BMY

About

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. It operates in BioPharmaceuticals. Its products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities... (more)

Overall

Beta: 0.33
Market Cap (Mil.): $101,683.00
Shares Outstanding (Mil.): 1,658.78
Dividend: 0.37
Yield (%): 2.41

Financials

  BMY Industry Sector
P/E (TTM): 37.65 37.83 38.47
EPS (TTM): 1.63 -- --
ROI: 10.17 18.99 18.25
ROE: 18.19 19.75 19.13
Search Stocks

High rate of lymphoma patients respond to Bristol-Myers drug: study

- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

06 Dec 2014

High rate of lymphoma patients respond to Bristol-Myers drug-study

Dec 6 - Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday.

06 Dec 2014

FDA declines to approve Bristol-Myers hepatitis drug

- Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve the use of its experimental treatment for hepatitis C, daclatasvir, in combination with other antiviral drugs.

26 Nov 2014

UPDATE 1-FDA declines to approve Bristol-Myers hepatitis drug

(Adds details on drug, other Bristol-Myers, rival treatments)

26 Nov 2014

FDA declines to approve Bristol-Myers hepatitis drug

Nov 26 - Bristol-Myers Squibb Co on Wednesday said U.S. regulators had declined to approve use of its experimental daclatasvir drug for hepatitis C, in combination with other antiviral drugs.

26 Nov 2014

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

17 Nov 2014

RPT-Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

Nov 16 - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

17 Nov 2014

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

16 Nov 2014

Bristol-Myers immunotherapy shows promise to replace chemo for melanoma

Nov 16 - Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results.

16 Nov 2014

UPDATE 2-Lonza shares drop after revenue forecast cut on weak water business

* Shares fall as much as 8.5 pct (Recasts with fall in shares, adds analyst comments)

31 Oct 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $105.55 -1.26
Pfizer Inc. (PFE.N) $31.94 -0.03
Merck & Co., Inc. (MRK.N) $59.58 +0.60
Sanofi SA (SASY.PA) €75.38 -0.79
AstraZeneca plc (AZN.L) 4,565.00p -7.50
GlaxoSmithKline plc (GSK.L) 1,392.00p +13.50
Eli Lilly and Co (LLY.N) $72.40 -0.05

Earnings vs. Estimates

Search Stocks